| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
*
Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom; and
Wellcome Trust Laboratories for Molecular Parasitology, Department of Biochemistry, Imperial College of Science, Technology and Medicine, London, United Kingdom
Vaccination against visceral leishmaniasis has received
limited attention compared with cutaneous leishmaniasis, although the
need for an effective vaccine against visceral leishmaniasis is
pressing. In this study, we demonstrate for the first time that a
recombinant stage-specific hydrophilic surface protein of
Leishmania donovani, recombinant hydrophilic acylated
surface protein B1 (HASPB1), is able to confer protection against
experimental challenge. Protection induced by rHASPB1 does not require
adjuvant and, unlike soluble Leishmania Ag + IL-12,
extends to the control of parasite burden in the spleen, an organ in
which parasites usually persist and are refractory to a broad range of
immunological and chemotherapeutic interventions. Both
immunohistochemistry (for IL-12p40) and enzyme-linked immunospot assay
(for IL-12p70) indicate that immunization with rHASPB1 results in IL-12
production by dendritic cells, although an analysis of Ab isotype
responses to rHASPB1 suggests that this response is not sufficient in
magnitude to induce a polarized Th1 response. Although both vaccinated
and control-infected mice have equivalent frequencies of
rHASPB1-specific CD4+ T cells producing IFN-
,
vaccine-induced protection correlates with the presence of
rHASPB1-specific, IFN--producing CD8+ T cells. Thus, we
have identified a novel vaccine candidate Ag for visceral
leishmaniasis, which appears to operate via a mechanism similar to that
previously associated with DNA vaccination.
This article has been cited by other articles:
|
|
 |
|
  A. Dey, P. Sharma, N. S. Redhu, and S. Singh Kinesin Motor Domain of Leishmania donovani as a Future Vaccine Candidate Clin. Vaccine Immunol., May 1, 2008; 15(5): 836 - 842. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Bhowmick, R. Ravindran, and N. Ali gp63 in Stable Cationic Liposomes Confers Sustained Vaccine Immunity to Susceptible BALB/c Mice Infected with Leishmania donovani Infect. Immun., March 1, 2008; 76(3): 1003 - 1015. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Maroof and P. M. Kaye Temporal Regulation of Interleukin-12p70 (IL-12p70) and IL-12-Related Cytokines in Splenic Dendritic Cell Subsets during Leishmania donovani Infection Infect. Immun., January 1, 2008; 76(1): 239 - 249. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Basu, S. Bhaumik, A. K. Haldar, K. Naskar, T. De, S. K. Dana, P. Walden, and S. Roy Hybrid Cell Vaccination Resolves Leishmania donovani Infection by Eliciting a Strong CD8+ Cytotoxic T-Lymphocyte Response with Concomitant Suppression of Interleukin-10 (IL-10) but Not IL-4 or IL-13 Infect. Immun., December 1, 2007; 75(12): 5956 - 5966. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. N. Coler, Y. Goto, L. Bogatzki, V. Raman, and S. G. Reed Leish-111f, a Recombinant Polyprotein Vaccine That Protects against Visceral Leishmaniasis by Elicitation of CD4+ T Cells Infect. Immun., September 1, 2007; 75(9): 4648 - 4654. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. K. TONUI and R. G. TITUS CROSS-PROTECTION AGAINST LEISHMANIA DONOVANI BUT NOT L. BRAZILIENSIS CAUSED BY VACCINATION WITH L. MAJOR SOLUBLE PROMASTIGOTE EXOGENOUS ANTIGENS IN BALB/C MICE Am J Trop Med Hyg, March 1, 2007; 76(3): 579 - 584. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. R. A. Martins, S. M. B. Jeronimo, J. E. Donelson, and M. E. Wilson Leishmania chagasi T-Cell Antigens Identified through a Double Library Screen Infect. Immun., December 1, 2006; 74(12): 6940 - 6948. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Ato, A. Maroof, S. Zubairi, H. Nakano, T. Kakiuchi, and P. M. Kaye Loss of Dendritic Cell Migration and Impaired Resistance to Leishmania donovani Infection in Mice Deficient in CCL19 and CCL21 J. Immunol., May 1, 2006; 176(9): 5486 - 5493. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Prickett, P. M. Gray, S. L. Colpitts, P. Scott, P. M. Kaye, and D. F. Smith In vivo recognition of ovalbumin expressed by transgenic leishmania is determined by its subcellular localization. J. Immunol., April 15, 2006; 176(8): 4826 - 4833. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Breton, M. J Tremblay, M. Ouellette, and B. Papadopoulou Live Nonpathogenic Parasitic Vector as a Candidate Vaccine against Visceral Leishmaniasis Infect. Immun., October 1, 2005; 73(10): 6372 - 6382. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Theinert, R. Basu, M. Forgber, S. Roy, S. Sundar, and P. Walden Identification of New Antigens in Visceral Leishmaniasis by Expression Cloning and Immunoblotting with Sera of Kala-Azar Patients from Bihar, India Infect. Immun., October 1, 2005; 73(10): 7018 - 7021. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. L. Meier, M. Svensson, and P. M. Kaye Leishmania-Induced Inhibition of Macrophage Antigen Presentation Analyzed at the Single-Cell Level J. Immunol., December 15, 2003; 171(12): 6706 - 6713. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Stager, J. Alexander, K. C. Carter, F. Brombacher, and P. M. Kaye Both Interleukin-4 (IL-4) and IL-4 Receptor {alpha} Signaling Contribute to the Development of Hepatic Granulomas with Optimal Antileishmanial Activity Infect. Immun., August 1, 2003; 71(8): 4804 - 4807. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. P. Price, M. R. Menon, C. Panethymitaki, D. Goulding, P. G. McKean, and D. F. Smith Myristoyl-CoA:Protein N-Myristoyltransferase, an Essential Enzyme and Potential Drug Target in Kinetoplastid Parasites J. Biol. Chem., February 21, 2003; 278(9): 7206 - 7214. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ahmed, M. Colmenares, L. Soong, K. Goldsmith-Pestana, L. Munstermann, R. Molina, and D. McMahon-Pratt Intradermal Infection Model for Pathogenesis and Vaccine Studies of Murine Visceral Leishmaniasis Infect. Immun., January 1, 2003; 71(1): 401 - 410. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. N. Coler, Y. A. W. Skeiky, K. Bernards, K. Greeson, D. Carter, C. D. Cornellison, F. Modabber, A. Campos-Neto, and S. G. Reed Immunization with a Polyprotein Vaccine Consisting of the T-Cell Antigens Thiol-Specific Antioxidant, Leishmania major Stress-Inducible Protein 1, and Leishmania Elongation Initiation Factor Protects against Leishmaniasis Infect. Immun., August 1, 2002; 70(8): 4215 - 4225. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Papadopoulou, G. Roy, M. Breton, C. Kundig, C. Dumas, I. Fillion, A. K. Singh, M. Olivier, and M. Ouellette Reduced Infectivity of a Leishmania donovani Biopterin Transporter Genetic Mutant and Its Use as an Attenuated Strain for Vaccination Infect. Immun., January 1, 2002; 70(1): 62 - 68. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. C. Melby, J. Yang, W. Zhao, L. E. Perez, and J. Cheng Leishmania donovani p36(LACK) DNA Vaccine Is Highly Immunogenic but Not Protective against Experimental Visceral Leishmaniasis Infect. Immun., August 1, 2001; 69(8): 4719 - 4725. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
